The US Food and Drug Administration (FDA) has approved the humanized monoclonal antibody romosozumab (Evenity, Amgen) for treatment of osteoporosis in postmenopausal women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.
快樂小藥師 發表在 痞客邦 留言(0) 人氣(948)
The US Food and Drug Administration today granted accelerated approval to atezolizumab (Tecentriq, Genentech/Roche) plus the chemotherapy nab-paclitaxel (Abraxane, Celgene) for the first-line treatment of unresectable locally advanced or metastatic, PD-L1-positive triple-negative breast cancer(TNBC).
快樂小藥師 發表在 痞客邦 留言(0) 人氣(466)
之前FDA已經發佈過聲明
FDA Medwatch]Benzocaine Topical Products: Sprays, Gels and Liquids - Risk of Methemoglobinemia(Benzocaine局部產品可能會增加變性血紅素血症的風險)快樂小藥師 發表在 痞客邦 留言(0) 人氣(99)
Faces of Schizophrenia You May Know快樂小藥師 發表在 痞客邦 留言(0) 人氣(1,367)
It’s Mosquito Season: The 411 on Repellents
快樂小藥師 發表在 痞客邦 留言(0) 人氣(571)
The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) blockade has demonstrated efficacy in patients with Hodgkin lymphoma (HL), according to researchers here at the American Society of Hematology (ASH) 56th Annual Meeting.
The strategy has previously produced impressive results in melanoma, non–small cell lung cancer, and other solid tumors.
快樂小藥師 發表在 痞客邦 留言(0) 人氣(306)
AIDS Memorial Quilt on display at the National Mall in Washington, D.C.
AIDS-related illnesses have killed more than 39 million people worldwide since 1981. And it's not over. About 1.1 million Americans are among the 35 million people worldwide who are now living with HIV, the virus that causes AIDS. How did we get here?
快樂小藥師 發表在 痞客邦 留言(0) 人氣(413)
快樂小藥師 發表在 痞客邦 留言(0) 人氣(354)
Over the past decade, complementary and alternative medicine (CAM) has grown into a multi-billion-dollar industry in the United States, with the use of CAM interventions becoming increasingly popular among cancer patients.
Studies estimate that at least half of cancer patients use some type of complementary intervention,[1] though the reported range varies from less than 10% to more than 60%.[2] The number of patients who seek out alternative therapies is quite low, with experts estimating that the percentage falls in the single digits.
快樂小藥師 發表在 痞客邦 留言(0) 人氣(200)
A new position statement from the American Diabetes Association (ADA) provides the first-ever guidance specific to the management of type 1 diabetes in all age groups, including a new HbA
1c target for children.
"Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association" was released June 16 at a press briefing held during the
American Diabetes Association 2014 Scientific Sessions and also simultaneously
published online in
Diabetes Care.
快樂小藥師 發表在 痞客邦 留言(0) 人氣(83)
醫藥類 (14)